Andrew C Patterson

US Patent:

7917387, Mar 29, 2011

Filed:

Mar 23, 2005

Appl. No.:

11/087469

Inventors:

Charles L. Spurr - Wakefield MA, US
Jim Giza - Sutton MA, US
Paul English - Arlington MA, US
Daniel S. Hafner - Fairfield CT, US
Andrew Patterson - New York NY, US

Assignee:

Kayak Software Corporation - Norwalk CT

International Classification:

G06Q 30/00

US Classification:

705 1424

Abstract:

Suppliers of goods and/or services subject to shifts in capacity utilization design and implement marketing campaigns around utilization forecasts, targeting marketing expenditures on periods of excess capacity rather than periods without excess capacity, and in some embodiments also to alter variables such as pricing, consumer targeting, or even the intensity of the campaign itself on a dynamic basis in response to changing market conditions.

US Patent:

8583485, Nov 12, 2013

Filed:

Feb 22, 2011

Appl. No.:

13/032558

Inventors:

Charles L. Spurr - Wakefield MA, US
Jim Giza - Sutton MA, US
Paul English - Arlington MA, US
Daniel S. Hafner - Fairfield CT, US
Andrew Patterson - New York NY, US
Steve Hafner - Fairfield CT, US

Assignee:

Kayak Software Corporation - Norwalk CT

International Classification:

G06Q 30/00

US Classification:

705 1443

Abstract:

Suppliers of goods and/or services subject to shifts in capacity utilization design and implement marketing campaigns around utilization forecasts, targeting marketing expenditures on periods of excess capacity rather than periods without excess capacity, and in some embodiments also to alter variables such as pricing, consumer targeting, or even the intensity of the campaign itself on a dynamic basis in response to changing market conditions.

US Patent:

20220402904, Dec 22, 2022

Filed:

Dec 16, 2020

Appl. No.:

17/124127

Inventors:

- Basel, CH
Jennifer Stroka COBB - Stow MA, US
Natalie DALES - Arlington MA, US
John Ryan KERRIGAN - Wakefield MA, US
Philip LAM - Somerville MA, US
Hasnain Ahmed MALIK - Boston MA, US
Gary O'BRIEN - Maynard MA, US
Andrew W. PATTERSON - Somerville MA, US
Noel Marie-France THOMSEN - Chelmsford MA, US
Pamela TING - Cambridge MA, US

International Classification:

C07D 413/14
C07D 401/14
C07D 471/04
C07D 417/14
A61K 45/06

Abstract:

The present disclosure relates to compounds of formula (I′) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

US Patent:

20230108325, Apr 6, 2023

Filed:

Mar 14, 2022

Appl. No.:

17/693759

Inventors:

- Basel, CH
Jennifer Stroka Cobb - Stow MA, US
Natalie Alysia Dales - Arlington MA, US
Janetta Dewhurst - Framingham MA, US
Matthew James Hesse - Oakland CA, US
Rama Jain - Danville CA, US
John Ryan Kerrigan - Wakefield MA, US
Hasnain Ahmed Malik - Boston MA, US
James R. Manning - Emeryville CA, US
Gary O'Brien - Maynard MA, US
Andrew W. Patterson - Somerville MA, US
Noel Marie-France Thomsen - Chelmsford MA, US
Pamela YF TING - Somerville MA, US

International Classification:

C07D 403/14
C07D 405/14
C07D 417/14
A61P 7/00

Abstract:

The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

US Patent:

20190390196, Dec 26, 2019

Filed:

Jan 16, 2019

Appl. No.:

16/249128

Inventors:

- Basel, CH
Marcel Blommers - Basel, CH
Cesar Fernandez - Basel, CH
Erin Geno - Cambridge MA, US
Alvar Gossert - Basel, CH
Paulette Greenidge - Basel, CH
Dieter Huesken - Basel, CH
Juerg Hunziker - Basel, CH
Francois Jean-Charles Natt - Basel, CH
Anup Patnaik - Cambridge MA, US
Andrew Patterson - Cambridge MA, US
Jean-Michel Rene Rondeau - Basel, CH
Jan Weiler - Cambridge MA, US
Meicheng Zhu - Cambridge MA, US

Assignee:

Novartis AG - Basel

International Classification:

C12N 15/11
C07C 69/40
C07C 233/01
C07C 43/23
C07D 213/30
C07D 401/04
C07D 217/18
C07D 217/16
C07D 217/14
C07D 311/80
C07D 215/14
C07D 215/12

Abstract:

The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3′ end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

US Patent:

20160304863, Oct 20, 2016

Filed:

Oct 1, 2014

Appl. No.:

15/025779

Inventors:

Jeremy Lee BARYZA - Cambridge MA, US
Marcel BLOMMERS - Basel, CH
Cesar FERNANDEZ - Basel, CH
Erin GENO - Cambridge MA, US
Alvar GOSSERT - Basel, CH
Paulette GREENIDGE - Basel, CH
Dieter HUESKEN - Basel, CH
Juerg HUNZIKER - Basel, CH
Francois Jean-Charles NATT - Basel, CH
Anup PATNAIK - Cambridge MA, US
Andrew PATTERSON - Cambridge MA, US
Jean-Michel Rene RONDEAU - Basel, CH
Jan WEILER - Cambridge MA, US
Meicheng ZHU - Cambridge MA, US

International Classification:

C12N 15/11
C07C 233/01
C07D 217/18
C07D 215/14
C07D 217/16

Abstract:

The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3′ end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

US Patent:

20160244756, Aug 25, 2016

Filed:

Oct 6, 2014

Appl. No.:

15/025826

Inventors:

Jeremy Lee BARYZA - Cambridge MA, US
Marcel BLOMMERS - Basel, CH
William CHUTKOW - Cambridge MA, US
Cesar FERNANDEZ - Basel, CH
Erin GENO - Cambridge MA, US
Alvar GOSSERT - Basel, CH
Paulette GREENIDGE - Basel, CH
Dieter HUESKEN - Basel, CH
Juerg HUNZIKER - Basel, CH
Francois Jean-Charles NATT - Basel, CH
Anup PATNAIK - Cambridge MA, US
Andrew PATTERSON - Cambridge MA, US
Jean-Michel Rene RONDEAU - Basel, CH
Jan WEILER - Cambridge MA, US
Meicheng ZHU - Cambridge MA, US

International Classification:

C12N 15/113

Abstract:

The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap. In various embodiments, the RNAi agents comprise a first and a second strand, wherein each strand is a 30-mer or shorter, the first strand comprises ribonucleotides, and the second strand comprises ribonucleotides and one or more spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand. In some embodiments, the 3 end of both strands further comprise, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker; and a 3 end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3 end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the first two base-pairing nucleotides on the 3 end of the one or both strand are 2-MOE. Optionally, the RNAi agent can be modified on one or both 5 end. Optionally, the first or second strand is the sense strand, and the sense strand can comprise a 5 end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

US Patent:

20160215288, Jul 28, 2016

Filed:

Sep 30, 2014

Appl. No.:

15/025852

Inventors:

Jeremy Lee Baryza - Cambridge MA, US
Marcel Blommers - Basel, CH
Cesar Femandez - Basel, CH
Erin Geno - Cambridge MA, US
Alvar Gossert - Basel, CH
Paulette Greenidge - Basel, CH
Dieter Huesken - Basel, CH
Juerg Hunziker - Basel, CH
Francois Jean-Charles Natt - Basel, CH
Anup Patnaik - Cambridge MA, US
Andrew Patterson - Cambridge MA, US
Jean-Michel Rene Rondeau - Basel, CH
Jan Weiler - Cambridge MA, US
Meicheng zhu - Leominster MA, US
Meghan Holdorf - Emeryville CA, US

International Classification:

C12N 15/113

Abstract:

The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3′ end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. In some embodiments, the 3′ end of both the sense and anti-sense strand further comprise, in 5′ to 3′ order: a spacer; a second phosphate or modified internucleoside linker; and a 3′ end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3′ end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker. Optionally, the RNAi agent can be modified on one or both 5′ end. Optionally, the sense strand can comprise a 5′ end cap which reduces the amount of the RNA interference mediated by this strand. Optionally, the RNAi agent is attached to a ligand. This format can be used to devise RNAi agents to a variety of different targets and sequences. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference. The disclosure also pertains to methods of treating, ameliorating and preventing HBV in a patient involving the step of administering to the patient a therapeutic amount of a HBV RNAi agent.